SCHEMBL9955261

SCHEMBL9955261

Cc1ccc(NC(=N)N)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.46
KCNQ3 O43525 1/20 0.45
KCNQ2 O43526 1/20 0.45
ADRA2A P08913 2/20 0.43
ADRA2B P18089 2/20 0.43
ADRA2C P18825 2/20 0.43
SORT1 Q99523 1/20 0.42
PIK3CA P42336 3/20 0.41
MTOR P42345 3/20 0.41
DDX3X O00571 1/20 0.39
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
FPR2 P25090 1/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC6 Q9UBN7 1/20 0.38
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4007229 0.81 NPSR1 (0.54) NPSR1KCNQ3KCNQ2ADRA2AADRA2B
SCHEMBL1889417 0.81 NPSR1 (0.47) NPSR1KCNQ3KCNQ2ADRA2AADRA2B
SCHEMBL9955661 0.78 ADRA2A (0.33) ADRA2AADRA2BADRA2CNPC1RAB9A
SCHEMBL4029126 0.77 KCNQ3 (0.51) KCNQ3KCNQ2ADRA2AADRA2BADRA2C
SCHEMBL23245943 0.77 TRPV1 (0.45) PIK3CAMTORALDH1A1GAASMN1; SMN2
SCHEMBL9954855 0.77 KMT2A (0.56) NPC1ALDH1A1GAARAB9ASMN1; SMN2
SCHEMBL29618383 0.77 TRPV1 (0.45) PIK3CAMTORALDH1A1GAASMN1; SMN2
SCHEMBL2242286 0.76 NPSR1 (0.57) NPSR1KCNQ3KCNQ2SORT1PIK3CA
SCHEMBL30919458 0.76 NPSR1 (0.57) NPSR1KCNQ3KCNQ2SORT1PIK3CA
SCHEMBL8974170 0.76 PTPN1 (0.51) ADRA2AADRA2BNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178739-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
WO-2012085166-A1 METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-06-28 WO disclosed
US-20110039820-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178739-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS PRKCI, PIK3CA, AKT1 NPSR1 4631/4885KCNQ3 3201/4885KCNQ2 3057/4885
US-20110039820-A1 LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS PRKCI, PIK3CA, AKT1 NPSR1 4631/4885KCNQ3 3201/4885KCNQ2 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.